Humacyte Submits Supplemental Biologics License Application to FDA for the Acellular Tissue Engineered Vessel in Dialysis Access
–sBLA submission seeks to add arteriovenous access for hemodialysis as second approved indication for the ATEV. –sBLA supported by results from three Phase 3 studies in hemodialysis access.
